Press Releases

investors hero background type
May 16 2024
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, May 16, 2024 (GLOBE NEWSWIRE) -- Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code:
Apr 10 2024
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, April 10, 2024 (GLOBE NEWSWIRE) -- Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code:
Apr 02 2024
Established recommended Phase 2 dose of NBTXR3 for the treatment of patients with inoperable, recurrent non-small cell lung cancer (“NSCLC”) who have previously received definitive radiation therapy Confirmation of injection feasibility and favorable safety profile in completed Phase 1 dose

For inquiries about our technology, collaborations, clinical trials, or other topics, we encourage you to get in touch with our team.